Get all premium features to the best stock analysis tool

Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago

Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate

— Represents Biomerica's First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy  — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated 18% vs. 11% Globally — Up to Five Million Canadians May Have IBS, Representing a Significant and Underserved Market Opportunity

IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2026 ended February 28, 2026.

IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced it has received its first commercial order for Hp Detect™, its Helicobacter pylori (H. pylori) diagnostic stool antigen test, from one of the largest clinical laboratory chains operating across Europe. The initial order is for the United Kingdom market, where Hp Detect™ received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026.

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized. Disease Burden: The WHO designates H.

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial. CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.